Loading...
Loading...
SANA| Name | Value |
|---|---|
| Revenues | 0.0M |
| Cost of Revenue | 7.8M |
| Gross Profit | -7.8M |
| Operating Expense | 116.3M |
| Operating I/L | -116.3M |
| Other Income/Expense | 2.3M |
| Interest Income | 2.4M |
| Pretax | -114.0M |
| Income Tax Expense | -6.8M |
| Net Income/Loss | -114.0M |
Sana Biotechnology, Inc. is a biotechnology company specializing in engineered cell therapies for various medical needs. Their product pipeline includes SG295 and SG242 targeting CD19+ cancer cells, SG221 and SG239 for multiple myeloma, SG328 for ornithine transcarbamylase deficiency, SG418 for sickle cell disease and beta-thalassemia, SC291 for CD19 allogeneic T cell therapy, SC255 for multiple myeloma, SC451 for type I diabetes mellitus, and SC379 for secondary progressive multiple sclerosis, Pelizaeus-Merzbacher disease, and Huntington's disease.
